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OBJECTIVES: Older adults are in an increased risk of respiratory infections includ-
ing community acquired pneumonia (CAP). The former socialistic countries of the
central Europe form a unique region with specific health care and epidemiology
characteristics, and where the local evidence on the underlying epidemiology is
scarce. The objective was to estimate the economic burden of CAP in adults 50
years of age in the Czech Republic (CR), Slovakia (SK), Poland (PL), andHungary (HU)
using data from 2010. METHODS: The incidence of hospitalized CAP stratified by
age groups 50-64, 65-74, 75-84 and 85 was obtained from national surveillance
systems (PL, CR, SK) and insurance records (HU). The estimates of non-hospitalised
CAP incidence was based on retrospective chart reviews (CZ, SK, PL) and the insur-
ance fund records (HU). Direct costs from the payer’s perspective were based on
resource use analyses (CR, SK), DRG lists (PL) and the insurance records (HU).
RESULTS: The incidence of hospitalized CAP per 100,000 person years was: 456.6
(CR), 504.6 (SK), 363.9 (PL), and 845.3 (HU). Compared with adults 50-64 years of age,
the incidence of hospitalised CAPwere 2.3 fold higher in those 65-74, 5.2 fold higher
in 75-84 and 10.8 fold higher in those85,manifesting an exponential trend.While
the majority of CAP among adults 50-64 years of age was treated outpatient, the
proportion of CAP hospitalized increased with increasing age. The total burden of
CAP in adults over 50 was € 12,579,543 (CR); 9,160,774 (SK); 22,409,085 (PL); and
18,298,449 (HU); with hospitalization representing over 90% of the direct costs of
treatment in all 4 countries. Adults 65, who represent 41% of the combined pop-
ulation, account for 73% of the costs. CONCLUSIONS: The incidence and likelihood
of hospitalisation drives the costs of CAP upwards with increasing age in the new
central EU countries.
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OBJECTIVES: Menopause symptoms are a good disease severity proxy for meno-
pausal women, but are not available in claims database. We applied probabilistic
linkage to add symptoms recorded in a registry database to claims data, and com-
pare the healthcare costs among women with various symptoms. METHODS:
Women age 45 or older who used estrogen only hormone therapy (HT) were se-
lected from a large US claims database (41/2005-09/30/2008). Another group who
used estrogen only HT with a menopause diagnosis was selected from the Univer-
sity of Michigan Women’s Registry Database. Logistic regression was used to cal-
culate the propensity score for each patient controlling for osteoporosis, gyneco-
logical disorders/procedures, genital infection, bladder/pelvic floor support
problem, gynecology system cancer, breast condition, gut condition, hormone dis-
order, nerve problem, and other individual comorbidities such as rheumatoid dis-
ease, depression, and blood clotting. Patients with the closest propensity score
from each group were matched, and menopause symptoms for registry patients
were added to the claims database records. After repeating probabilistic linkage
250 times, themean and 95% confidence interval (CI) of healthcare costs during the
follow-up periodwere calculated. RESULTS: 80 patients from each populationwere
matched after probabilistically linking 20,020 claims database patients with 83
registry database patients. The average cost of patients with at least one symptom
was much higher than for patients without symptoms ($13,570 [95% CI: $13,459-
$13,680] vs. $3,391 [95%CI: $3,345-$3,436], p-value0.001). Cost differences were
mainly from inpatient, physician visit, and pharmacy costs. Among patients with
menopause symptoms, those with hot flashes had the highest costs ($10,127), fol-
lowed by memory loss ($1,653), vaginal dryness ($864), reduced libido ($568), and
mood swings ($358). CONCLUSIONS: Women with menopause symptoms incur
higher health care costs than those without This study suggests symptoms are
important determinants of health care expenses and their impact can be assessed
by linking registry and claims databases.
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OBJECTIVES: To evaluate the long-term cost-effectiveness of a fixed-dose combi-
nation (FDC) therapy (0.5mg dutasteride and 0.4mg tamsulosin daily) compared to
0.4mg tamsulosinmonotherapy for the treatment of symptomatic benign prostatic
hyperplasia (BPH).METHODS:We developed a Markov state transition model with
tunnel state and embedded decision tree. The model follows a Quebec cohort of
312,448 male patients aged 50 years, diagnosed with BPH and with symptoms as
defined by an International Prostate Symptom Score 12. This cohort reflects the
population of the 4-year ComBAT trial to evaluate the effect of combination ther-
apy versus either dutasteride or tamsulosin monotherapy on BPH clinical progres-
sion and improvement in BPH symptoms. We conduct this analysis from the per-
spective of the Quebec provincial healthcare system, considering all primary care
and hospital costs. Utility estimates were obtained from published literature. Re-
sults are presented at 10 years and lifetime (up to 25 years) in the form of incre-
mental costs, incremental QALYs and the incremental cost-effectiveness ratio
(ICER). Sensitivity analyses were performed to evaluate the robustness of the
model to variations in the underlying input parameters. RESULTS: Discounted
QALYs per patient at a 10-year time horizon were 6.88 (FDC) and 6.82 (Tamsulosin).
At 10 years the ICER for FDC comparedwith Tamsulosinwas CAD $29,860. The ICER
decreased over time to reach CAD $29,239 over a lifetime horizon. At a willingness
to pay of CAD $50,000 per QALY gained, the probability of FDC being cost-effective
for the symptomatic BPH population was approximately 63%. CONCLUSIONS: FDC
can be cost-effective in treating patients affectedwith enlarged prostatewithmod-
erate or severe symptoms. The sensitivity analyses suggested that variation in
main parameters will not alter the behavior of the comparison between the two
treatments (i.e. FDC is always more effective andmore costly than tamsulosin at a
lifetime time horizon).
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OBJECTIVES:Despite the Ecuadorian policy of vaccination for high risk persons and
adults over 50 years age with 23-valent pneumococcal polysaccharide vaccine
(PPSV23), Streptococcus pneumonia infections continue to be the most common dis-
ease, causing approximately 3,158 deaths every year and raising public health
costs. A 13 valent pneumococcal conjugate vaccine (PCV13) has recently been ap-
proved for use in adults, and is expected to have an additional impact on disease
burden due to covered serotypes. The purpose of this studywas to compare PPSV23
and PCV13 vaccines from an Ecuadorian public perspective. METHODS: A cost-
effectiveness analysis based on a Markov model was developed comparing the
impact and cost-effectiveness of PPSV23 and PCV13 for the prevention of pneumo-
coccal disease in high risk adult population. Time horizon of the model was 35
years, with annual discounting of 5% per annum. The effectiveness measure was
the number of cases avoided and cost differences between the interventions. Re-
source use and costs were obtained from Ministry of Health published data, INEC,
and SIREVA reports. Costs were collected from local healthcare databases.
RESULTS: The model reveals that PCV13 is a cost-saving alternative compared to
PPSV23. Vaccinationwith PCV13 is estimated to prevent an additional 1443 cases of
bacteremia; 162 cases of meningitis; 11,236 cases of inpatient pneumonia; 1,241
cases of outpatient pneumonia and 3413 deaths due disease compared to PPSV23.
Furthermore, vaccination with PCV13 is estimated to save thousands: 25,329 USD
in medical costs, 3,874 USD in non medical costs and 46.027 USD in medical non
medicalvaccination costs. CONCLUSIONS: In Ecuador, a national policy of vacci-
nation with PCV13 is expected to be a cost-saving strategy in the prevention of
pneumococcal disease in high risk patients and adults over 50 years compared to
PPSV23. PPV13 is expected to generate reduction on mortality and morbidity with
lower expected costs.
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OBJECTIVES: To conduct a cost-effectiveness analysis of a universal childhood
hepatitis A vaccination program in Brazilian regions with different hepatitis A
endemicity. METHODS: An age and time-dependent dynamic model was devel-
oped to estimate the incidence of hepatitis A for 24 years. The analysis was run
separately, according to the pattern of regional endemicity, one for Southern 
Southeast (low endemicity) and one for the North  Northeast  Midwest (inter-
mediate endemicity). The decision analysis model compared universal childhood
vaccination with current program of vaccinating high risk individuals. Epidemio-
logic and cost estimates were based on data retrieved from a nationwide seroepi-
demiological survey for viral hepatitis, primary data collection, National Health
Information Systems and literature. The analysis was conducted from the health-
care system and societal perspectives. Costs are expressed in 2008 Brazilian reals.
RESULTS: In this model a universal national immunization program would have a
significant impact on disease epidemiology in all regions, resulting in 64% reduc-
tion in the number of cases of icteric hepatitis, 59% reduction in deaths due to
disease and a 62 % decrease of life years lost, in a national perspective. With a
vaccine price per dose of R$16.89 (US$7.23), vaccination against hepatitis A was a
cost-saving strategy in the low and intermediate endemicity regions and in Brazil
as a whole from healthcare and society perspective. Results weremost sensitive to
icteric hepatitis incidence, ambulatory cases and vaccine costs. CONCLUSIONS:
Universal childhood vaccination program against hepatitis A could be a cost-sav-
ing strategy in all regions of Brazil. These results may be useful for the Brazilian
government for vaccine related decisions and for monitoring population impact if
the vaccine is included in the National Immunization Program.
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BACKGROUND: Utilization of In Vitro Fertilization (IVF) to treat infertility is in-
creasing, despite the high cost incurred, often resulting inmultiple birthswith poor
outcomes. Physicians practicing in states with insurance mandates have been
shown to transfer fewer embryos, resulting in fewer multiple births and improved
outcomes. OBJECTIVES: The objective of this study was to compare the impact of
mandated IVF insurance coverage on the cost per live birth of healthy infants and
infants born with disability. METHODS: A Markov model was developed to calcu-
late the number of live births resulting from a maximum of six IVF cycles, and
cumulative costs through initial hospital discharge. Age-specific utilization rates,
pregnancy rates, birth rates, multiple rates, and costs for states with and without
insurance mandates were derived from the literature, insurances claims data-
bases, and publicly available CDC data. Themodel takes a societal perspective and
reports results in 2010 US dollars. RESULTS: In hypothetical cohorts of 10,000, for
women under the age of 35-years, the insurance strategy results in 42 fewer births
with disability. The non-insurance strategy results in 31 additional healthy births
but at a cost of $1,831,462 per healthy birth. For women aged 35-37, the insurance
strategy dominates the non-insurance strategy with 12 additional births with dis-
ability, and 282 additional healthy births. For women aged 38-40, the insurance
strategy dominates the non-insurance strategy with 0 additional births with dis-
ability, and 46 additional healthy births. For women aged 41-42, the insurance
strategy results in 23 fewer births with disability, and 1 fewer healthy birth. The
cost for each additional healthy birth is $244,903,064. CONCLUSIONS: This study
shows insurance coverage for IVF is a “cost-effective”, and in some age groups a
dominant strategy, even in the short time horizon from delivery through initial
discharge and should be considered for inclusion as a standard insurance benefit.
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OBJECTIVES: This study provides the results from aminimization costsmodel that
compares the use of Dienogest with the use of GnRH antagonist in women with
Endometriosis diagnosis in Colombia and Argentina. METHODS: We used a cost
minimization model. The case base are women with endometriosis diagnosis in a
1 year time horizon. For the Colombian analysis we used a public perspective while
in Argentina we used a social work perspective and a prepaid medical services
perspective. The costs used in this model are direct costs and were obtained from
some insurers of Colombian and Argentinean health system. The colombian treat-
ment schedule is: 12-month use of Dienogest vs. 6-month use of the GnRH antag-
onist, and the Argentina treatment schedule is: 12-month use of Dienogest vs
6-month use of GnRH antagonist  6-month use of supportive treatment (treat-
ment schedule 1), or 12-monthuse ofDienogest vs 9-monthuse of GnRHantagonist
 9-month use of add-back treatment  3-month use of supportive treatment
(treatment schedule 2). RESULTS: For the case base studied, we found that in
Colombia the total treatment cost is US$986.19 with Dienogest and US$2855.57
with the GnRH antagonist. In the other hand in Argentina. The total treatment cost
for the treatment schedule 1 is US$534.57 with Dienogest and US$881 with the
GnRH antagonist from the social work perspective, and $490.75with Dienogest and
812.21 the GnRH antagonist from the prepaid medical services perspective. The
total treatment cost for the treatment schedule 2 is US$534.57 with Dienogest and
US$1488.28 with the GnRH antagonist from the social work perspective, and
$490.75 with Dienogest and US$1386.21 the GnRH antagonist from the prepaid
medical services perspective. CONCLUSIONS: The use of Dienogest minimizes the
total cost either in Colombia and Argentina from any perspective.
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OBJECTIVES: In Singapore, the default option for medical care among nursing
home (NH) residents at their end of life is hospital admission, incurring high
healthcare costs. Palliative care has been shown to reduce healthcare costs at the
end-of-life; however, NHs are not equipped to offer this. Project CARE was intro-
duced in 7 NHs by a hospital unit to provide palliative care for NH residents. Our
objective is to evaluate the cost impact of Project CARE on NH residents at the
end-of-life. METHODS: Project CARE was provided to a prospective cohort identi-
fied with a risk of dying within the next 1-year. A retrospective control group
deceasedwithin 2-years prior to the inception of Project CAREwas identified. Com-
parisons between Project CARE and routine care were made for the following time
points: 1- and 3-months prior to death. We adopted the health system perspective,
including the cost incurred for palliative care visits, hospitalization length of stay
(LOS), nursing home LOS, emergency visits, specialist visits and primary care visits.
Differences in cost at 1- and 3-months prior to death were analyzed using linear
regression of log transformed cost adjusting for patient characteristics. RESULTS:
A total of 429 residents (cases: 96, controls: 333) were included for the study. Mean
age of cases and controls were 85 and 82 years respectively. At 3 months prior to
death, Project CARE cost 2.5% (95% CI: -18.2%, 23.1%) more than the routine care. A
20% (95% CI: -42%, 1.8%) savings was observed at 1 month prior to death. However,
both observations were not statistically significant. CONCLUSIONS: Costs were not
significantly different between Project CARE and routine care. High start-up cost of
the programmight have offset savings from reduction in hospitalization. We pos-
tulate potential cost savings as the program reaches full capacity.
PIH22
QUALITY OF PEDIATRIC COST-UTILITY ANALYSES 1997-2009
Ungar W1, Kromm S2, Bethell J2, Kraglund F3, Edwards S2, Laporte A2, Coyte P2
1Hospital for Sick Children, Toronto, ON, Canada, 2University of Toronto, Toronto, ON, Canada,
3Dalhousie University, Halifax, NS, Canada
OBJECTIVES:High quality economic evidence is necessary for optimizing pediatric
health care allocation. The objectives were to appraise the quality of published
pediatric cost utility analyses (CUA). It was hypothesized that higher quality would
be associated with later publications, publication in a health economics/methods
journal and prospective utility assessment.METHODS: Pediatric CUAs published in
1997-2009 were assessed. Studies were retrieved from the Pediatric Economic Da-
tabase Evaluation project (PEDE), a comprehensive database of pediatric health
economic evaluations. Quality was assessed using the Pediatric Quality Appraisal
Questionnaire which scores 14 domains from 0 to 1. Higher domain scores indicate
better quality. Multiple linear regression was used to examine the effect of journal
type, whether utility was measured prospectively in the study, and year of publi-
cation on each domain score. RESULTS: There were 305 CUAs published over the
study interval. The annual number of pediatric CUAs increased over time. Most
studies were undertaken in North America and Europe. Infectious diseases and
their treatment and prevention was the most common therapeutic area (48%).
Young children (1 to 12 years old) were studied most often (39%). Utility was mea-
sured prospectively in only 8% of studies. Quality was appraised in a random sam-
ple of 213 CUAs. Mean domain scores ranged from 0.57 (Analysis) to a high of 0.91
(Target population). Studies published in methods/economics journals demon-
strated significantly higher scores for 7 domains (p0.05). Studies that measured
utility prospectively scored significantly higher on the Analysis domain. Multiple
regression results showed that quality of five domains improved over time
(p0.05). CONCLUSIONS:While quality in some domains improved over time, oth-
ers did not. Variability in quality of pediatric CUAs indicates that caution should be
exercised when interpreting results for decisionmaking. Challenges in conducting
economic evaluations in children, such as prospective utility measurement, re-
quire further research.
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OBJECTIVES:To examine in a retrospective study the incremental health care costs
of breast pain and endometrial bleeding among postmenopausal women pre-
scribed progestin containing Hormone Therapy (HT).METHODS:Women age 45 to
65 who were prescribed HT (01/01/2006-09/30/2008) were selected from a large US
claims database. The date of the first identifiedHTprescriptionwas assigned as the
index date. Patients were required to have at least 1 quarter of continuousmedical
and pharmacy benefits before and after the index date. Patients evidencing breast
pain and/or endometrial bleeding during the follow-up periodwere assigned to the
‘selected AEs’ cohort, and the remaining patients were assigned to the ‘no selected
AEs’ cohort. Patients were followed for at most 8 full quarters. A two-part model
using logistic regression and a mixed model with repeated measurements were
used in themultivariate analysis. Patients’ age,medication, procedures, andhealth
care costs during the pre-index period were adjusted in the model. Adjusted total
health care costs for each quarter, 1st and 2nd years of the follow-up period, and
average annual costs were provided. RESULTS: A total of 5,325 patients were in-
cluded in the ‘selected AEs’ cohort and 49,942 in the ‘no selected AEs’ cohort. After
adjusting for baseline differences, the adjusted quarterly costs ranged from $1944
to $2185 for the ‘selected AEs’ cohort and from $1699 to $1971 for the ‘no selected
AEs’ cohort. The quarterly health care cost differences between the two cohorts
were from $250 (p0.0001) at first quarter to $214 (p0.0001) at 8th quarter. The
adjusted annual health care costs were higher for patients with the selected AEs
($8195 vs. $7238; p0.0001).CONCLUSIONS: This study shows that the incremental
total health care costs associatedwith endometrial bleeding and breast pain are on
average $239 quarterly and $957 annually, in a US managed care setting.
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OBJECTIVES: Developed over the past 15 years, the Future Elderly Model (FEM) is a
demographic and economic model to predict future costs and health status for the
elderly. The present study updates the model by incorporating health behaviors,
which can have significant impacts on the use and value of new health care tech-
nologies. In addition, it extends the FEM to new disease areas, including: cognitive
impairment and Alzheimer’s; aging-related interventions; diabetes; socioeco-
nomic disparities; the health consequences of reimbursement for medical innova-
tions; and the productivity benefits of improved health in older populations.
METHODS:The FEMuses a representative sample of Americans aged 51, from the
Health and Retirement Study (HRS). Based on the observed risks and transitions in
the HRS, the FEM models how individuals grow old, acquire diseases and disabili-
ties, and die. The FEM is coupled with expert panels and reviews of the literature
designed to elicit the most likely scenarios for new technological changes.
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